Main Article Content
Objectives: The present study was designed to evaluate the role of CK2α; in prognosis of breast cancer patients diagnosed at the same stage of the disease, and to predict aggressiveness of the tumor.
Methods: A retroprospective immunohistochemical analysis of CK2α was carried out in human breast cancer tissue specimens. All the cases included were diagnosed at stage II of disease. χ 2 tests and Regression analysis were carried out to determine the correlation between histopathological parameters and expression pattern of CK2α
Results: There was a positive correlation between total as well as nuclear expression of CK2α with increasing Nottingham prognostic index (p<0.0001). CK2α was also found to be significantly associated with the lymph node metastasis (p<0.0001).
Conclusion: Immunohistochemical expression of CK2α can be used as an indicator of poor prognosis of disease even if overall stage of the breast cancer is the same. CK2α can also serve to predict the aggressiveness of the breast cancer as well and can identify the sub set of patients at high risk of developing lymph node metastasis.
Work published in KMUJ is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
2. Gietz RD, Graham KC, Litchfield DW. Interactions between the subunits of casein kinase II. J Biol Chem. 1995; 270(22):13017–21.
3. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001; 16(2):573–82.
4. Guerra B, Issinger O-G. Protein kinase CK2 in human diseases. Curr Med Chem. 2008; 15(19):1870–86.
5. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009; 66(11-12):1858–67.
6. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene. 2001; 20(25):3247–57.
7. Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem. 2001; 227(1-2):153–65.
8. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res. 2002; 62(15):4180–5.
9. Izeradjene K, Douglas L, Delaney A, Houghton JA. Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene. 2005; 24(12):2050–8.
10. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res. 2004; 2(12):712–21.
11. Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate. 1994; 24(1):11–6.
12. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes J-L, Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer. 2007; 43(5):928–34.
13. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med. 1995; 1(6):659–66.
14. Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol. 1999; 31(9):941–9.
15. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs. 2005; 16(10):1037–43.
16. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod S a. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014; 348(February):g366.
17. Kurshumliu F, Gashi-Luci L, Kadare S, Alimehmeti M, Gozalan U. Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression. World J Surg Oncol. 2014; 12(1):243.
18. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett. 1996; 101(1):31–5.
19. Unger GM, Davis AT, Slaton JW, Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets. 2004; 4(1):77–84.
20. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, et al. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors. 2010; 36(3):187–95.
21. Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, et al. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett. 2012; 315(1):48–58.
22. Rozanov D V, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S, et al. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res. 2008; 68(11):4086–96.
23. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003; 17(3):349–68.